Concinnity Genetics, a promising Edinburgh-based health tech spinout, has successfully raised £3 million in a funding round.
- Founded in 2023, the company focuses on developing innovative gene therapies with advanced control mechanisms.
- The investment round was led by Eos Advisory, with additional backing from Scottish Enterprise and other significant investors.
- The raised funds will be utilised to enhance the company’s technology and further its mission in safe and effective gene therapies.
- Concinnity Genetics aims to become a leading partner in gene control, ensuring the safety of gene and cell therapies.
Concinnity Genetics, established in Edinburgh in 2023, has quickly positioned itself at the forefront of health tech innovation by developing cutting-edge gene therapies. The company specialises in creating novel therapies equipped with control mechanisms designed to ensure maximum safety and efficacy.
The company recently closed a highly successful funding round, raising £3 million. This round was notable for being oversubscribed, demonstrating strong confidence from the investment community in Concinnity’s potential.
The investment was spearheaded by Eos Advisory, a well-respected Scottish investment firm known for supporting groundbreaking scientific ventures. Eos Advisory’s managing partner, Andrew McNeill, recognised Concinnity’s technology as having immense potential, describing it as the ‘holy grail for emerging gene therapies’.
Alongside Eos Advisory, Scottish Enterprise and Old College Capital, the University of Edinburgh’s own venture investment fund, provided additional financial support. Maven Capital Partners also contributed to the funding.
Jessica Birt, CEO and co-founder of Concinnity Genetics, expressed optimism about the infusion of capital, highlighting the crucial role these funds will play in further developing their technology. She credited ongoing support from Scottish Enterprise as testament to the belief in their innovative approach.
The University of Edinburgh’s involvement through Old College Capital underscores its commitment to leveraging engineering biology to solve critical health challenges. According to Dr Andrea Taylor, CEO of Edinburgh Innovations, sophisticated gene control systems offer exciting possibilities for creating advanced therapeutics that could transform healthcare.
These developments mark a significant step forward for Concinnity Genetics, as the funds and support received will enable them to push the boundaries of what is possible in gene control and therapy.
The successful funding round marks a pivotal moment for Concinnity Genetics as it embarks on further advancements in gene therapy.
